Symposium overview: Estrogens and antiestrogens in managing the patient with breast cancer

[1]  S. Cummings,et al.  The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial , 2000 .

[2]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[3]  S. Singletary,et al.  Special considerations in breast cancer risk and survival , 1999, Journal of surgical oncology.

[4]  T. Powles,et al.  Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial , 1998, The Lancet.

[5]  P. Boyle,et al.  Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women , 1998, The Lancet.

[6]  Mike Clarke,et al.  Tamoxifen for early breast cancer: an overview of the randomised trials , 1998, The Lancet.

[7]  S. Singletary,et al.  Use of aromatase inhibitors in postmenopausal women with advanced breast cancer , 1997, Journal of surgical oncology.

[8]  Julian Peto,et al.  Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer , 1997, The Lancet.

[9]  J. Manson,et al.  Postmenopausal hormone therapy and mortality. , 1997, The New England journal of medicine.

[10]  R. Theriault,et al.  Estrogen replacement therapy in women with prior diagnosis and treatment for breast cancer , 1997, Gynecologic oncology.

[11]  B Fisher,et al.  Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. , 1996, Journal of the National Cancer Institute.

[12]  G. Sarto,et al.  Hormone replacement therapy in the menopause: A pro opinion , 1996, CA: a cancer journal for clinicians.

[13]  C. Longcope,et al.  Relation of prediagnostic serum estrogen and androgen levels to breast cancer risk. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[14]  F Berrino,et al.  Serum sex hormone levels after menopause and subsequent breast cancer. , 1996, Journal of the National Cancer Institute.

[15]  G A Colditz,et al.  The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. , 1995, The New England journal of medicine.

[16]  P. Strax,et al.  A prospective study of endogenous estrogens and breast cancer in postmenopausal women. , 1995, Journal of the National Cancer Institute.

[17]  G. Fagerberg,et al.  Recurrence-free survival in patients with small breast cancer. An analysis of cancers 10 mm or less detected clinically and by screening. , 1994, The European journal of surgery = Acta chirurgica.

[18]  P. Disaia,et al.  Hormone replacement therapy In breast cancer , 1993, The Lancet.

[19]  T. Powles,et al.  Hormone replacement after breast cancer , 1993, The Lancet.

[20]  R. Opfell,et al.  Hormone replacement therapy in previously treated breast cancer patients. , 1993, American journal of surgery.

[21]  M. Green,et al.  Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  M. A. Hansen,et al.  Effect of salcatonin given intranasally on bone mass and fracture rates in established osteoporosis: a dose-response study. , 1992, BMJ.

[23]  Claus Christiansen,et al.  Diagnosis of Osteoporosis , 1992, Southern medical journal.

[24]  M. Pike,et al.  Serum hormone levels in pre-menopausal Chinese women in Shanghai and white women in Los Angeles: results from two breast cancer case-control studies , 1990, Cancer Causes & Control.

[25]  B. Stoll,et al.  TREATMENT OF MENOPAUSAL SYMPTOMS IN BREAST CANCER PATIENTS , 1988, The Lancet.

[26]  J. Wittliff.  Steroid‐hormone receptors in breast cancer , 1984, Cancer.

[27]  A. Dnistrian,et al.  Endocrine consequences of CMF adjuvant therapy in premenopausal and postmenopausal breast cancer patients , 1983, Cancer.

[28]  D. Gordon.  WOODPECKERS' TONGUES , 1976, The Lancet.

[29]  V. Jordan.  Effect of tamoxifen (ICI 46,474) on initiation and growth of DMBA-induced rat mammary carcinomata. , 1976, European journal of cancer.

[30]  A. Lacassagne,et al.  Hormonal Pathogenesis of Adenocarcinoma of the Breast , 1936 .

[31]  G. Beatson.  On the Treatment of Inoperable Cases of Carcinoma of the Mamma: Suggestions for a New Method of Treatment, with Illustrative Cases , 1896, Transactions. Medico-Chirurgical Society of Edinburgh.

[32]  L. Holmberg,et al.  Prognostic characteristics in breast cancers after hormone replacement therapy , 2005, Breast Cancer Research and Treatment.

[33]  Harry K. Genant,et al.  Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial , 2000 .

[34]  G. Hortobagyi,et al.  Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  T. Bush,et al.  A Case‐Control Study of Combined Continuous Estrogen—Progestin Replacement Therapy among Women with a Personal History of Breast Cancer , 1995 .

[36]  R. Theriault,et al.  Randomized prospective trial of estrogen-replacement therapy in women with a history of breast cancer. , 1994, Journal of the National Cancer Institute. Monographs.

[37]  J. Kanis,et al.  Perspective : The diagnosis of osteoporosis , 1994 .

[38]  M. Chapuy,et al.  VITAMINE D3 AND CALCIUM TO PREVENT HIP FRACTURE S IN ELDERLY WOMEN , 1992 .

[39]  Y. Nomura.  [Steroid hormone receptors in breast cancer]. , 1990, Rinsho byori. The Japanese journal of clinical pathology.